Cargando…

Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Arrhythmia is a common extra genital pathology in pregnant. Catheter ablation without fluoroscopy demonstrated similar efficacy and safety to fluoroscopy-based procedure. However, data on pregnant population is limited. PURPOSE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdrakhmanov, A, Ainabekova, B, Nuralinov, O, Smagulova, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207574/
http://dx.doi.org/10.1093/europace/euad122.237
_version_ 1785046487353262080
author Abdrakhmanov, A
Ainabekova, B
Nuralinov, O
Smagulova, A
author_facet Abdrakhmanov, A
Ainabekova, B
Nuralinov, O
Smagulova, A
author_sort Abdrakhmanov, A
collection PubMed
description FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Arrhythmia is a common extra genital pathology in pregnant. Catheter ablation without fluoroscopy demonstrated similar efficacy and safety to fluoroscopy-based procedure. However, data on pregnant population is limited. PURPOSE: To evaluate the arrhythmias substrate and outcomes of catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia. METHODS: 44 pregnant with drug refractory supraventricular tachycardia (Mean age 26.4±3.1 years, mean gestation age 22.8±2.1 weeks) undergoing catheter ablation. The substrate characteristics, course of pregnancy, outcomes and arrhythmia recurrence documented during 24 months follow-up. RESULTS: Ablation was performed under the guidance of CARTO (n=20; 45.5%) and EnSite NavX mapping systems (n=24; 54.5%) without fluoroscopy in all cases. In the majority of cases ablated substrate was slow conduction way (n=21, 47.7%). Ablation of accessory pathways performed in 18 pregnant (40.9%).Combination of accessory pathways with slow conduction ways was present in 5 women (11.4%). Accessory pathways located at left free wall (n=8), in right free wall (n=5), right medioseptal (n=5) and posteroseptal (n=5). The median procedural time was 71 minutes (interquartile range 60-89). Acute success rate was 100%. Procedure related complication was observed in one women (2.3%), who developed an ileofemoral thrombosis. There was no termination of pregnancy after ablation. In two women (4.5%) was preterm delivery at 35 and 36 weeks of gestation. In the majority of cases was vaginal delivery (n=35; 79.5%). In two cases were placental abruption and preeclampsia (4.5%). There were 45 live births (in one case were twins) without any malformation. Neonatal outcomes: fetal birth weight was 3198.5±542.5 grams, 5 minute Apgar score was 8.4±1.1. There were no maternal and fetal mortality. At follow up period arrhythmia recurrence was not documented. CONCLUSIONS: Pregnant mostly underwent catheter ablation for atrioventricular nodal reentrant tachycardia. Catheter ablation without fluoroscopy are safe and feasible in pregnant.
format Online
Article
Text
id pubmed-10207574
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102075742023-05-25 Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes Abdrakhmanov, A Ainabekova, B Nuralinov, O Smagulova, A Europace 11.4 - Treatment FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Arrhythmia is a common extra genital pathology in pregnant. Catheter ablation without fluoroscopy demonstrated similar efficacy and safety to fluoroscopy-based procedure. However, data on pregnant population is limited. PURPOSE: To evaluate the arrhythmias substrate and outcomes of catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia. METHODS: 44 pregnant with drug refractory supraventricular tachycardia (Mean age 26.4±3.1 years, mean gestation age 22.8±2.1 weeks) undergoing catheter ablation. The substrate characteristics, course of pregnancy, outcomes and arrhythmia recurrence documented during 24 months follow-up. RESULTS: Ablation was performed under the guidance of CARTO (n=20; 45.5%) and EnSite NavX mapping systems (n=24; 54.5%) without fluoroscopy in all cases. In the majority of cases ablated substrate was slow conduction way (n=21, 47.7%). Ablation of accessory pathways performed in 18 pregnant (40.9%).Combination of accessory pathways with slow conduction ways was present in 5 women (11.4%). Accessory pathways located at left free wall (n=8), in right free wall (n=5), right medioseptal (n=5) and posteroseptal (n=5). The median procedural time was 71 minutes (interquartile range 60-89). Acute success rate was 100%. Procedure related complication was observed in one women (2.3%), who developed an ileofemoral thrombosis. There was no termination of pregnancy after ablation. In two women (4.5%) was preterm delivery at 35 and 36 weeks of gestation. In the majority of cases was vaginal delivery (n=35; 79.5%). In two cases were placental abruption and preeclampsia (4.5%). There were 45 live births (in one case were twins) without any malformation. Neonatal outcomes: fetal birth weight was 3198.5±542.5 grams, 5 minute Apgar score was 8.4±1.1. There were no maternal and fetal mortality. At follow up period arrhythmia recurrence was not documented. CONCLUSIONS: Pregnant mostly underwent catheter ablation for atrioventricular nodal reentrant tachycardia. Catheter ablation without fluoroscopy are safe and feasible in pregnant. Oxford University Press 2023-05-24 /pmc/articles/PMC10207574/ http://dx.doi.org/10.1093/europace/euad122.237 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle 11.4 - Treatment
Abdrakhmanov, A
Ainabekova, B
Nuralinov, O
Smagulova, A
Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title_full Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title_fullStr Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title_full_unstemmed Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title_short Catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
title_sort catheter ablation without fluoroscopy in pregnant with supraventricular tachycardia: substrate characterization and outcomes
topic 11.4 - Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207574/
http://dx.doi.org/10.1093/europace/euad122.237
work_keys_str_mv AT abdrakhmanova catheterablationwithoutfluoroscopyinpregnantwithsupraventriculartachycardiasubstratecharacterizationandoutcomes
AT ainabekovab catheterablationwithoutfluoroscopyinpregnantwithsupraventriculartachycardiasubstratecharacterizationandoutcomes
AT nuralinovo catheterablationwithoutfluoroscopyinpregnantwithsupraventriculartachycardiasubstratecharacterizationandoutcomes
AT smagulovaa catheterablationwithoutfluoroscopyinpregnantwithsupraventriculartachycardiasubstratecharacterizationandoutcomes